Humacyte, Inc. (HUMA)
Healthcare · NMS · US
Price as at 1 Oct 2026, 05:51 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Humacyte, Inc. trades at $0.52. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
Our moat model scores it 12 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
HUMA earnings and analyst estimates
Recommendation mix, 5 published ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Humacyte, Inc.
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
HUMA passes 2 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
7 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$2.03M · 0.0% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$1.49M · 0.0% of book
- Ken Griffin, CITADEL ADVISORS LLC$1.13M · 0.0% of book
- Marshall Wace, MARSHALL WACE, LLP$141.8K · 0.0% of book
- Steve Cohen, Point72 Asset Management, L.P.$41.9K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Politician trades in HUMA
Trades in HUMA disclosed by members of Congress and executive-branch officials, latest first:
- Thomas H Tuberville · SenateSell · $15,001 - $50,000 · traded 3 May 2024 · disclosed 5 Aug 2026
- Thomas H Tuberville · SenateSell · $1,001 - $15,000 · traded 3 May 2024 · disclosed 5 Aug 2026
- Thomas H Tuberville · SenateBuy · $15,001 - $50,000 · traded 21 Mar 2024 · disclosed 5 Aug 2026
- Thomas H Tuberville · SenateBuy · $1,001 - $15,000 · traded 21 Mar 2024 · disclosed 5 Aug 2026
- Thomas H Tuberville · SenateBuy · $1,001 - $15,000 · traded 21 Mar 2024 · disclosed 5 Aug 2026
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
HUMA peers
The largest companies in the same industry (Biotechnology), then in the same sector.
- CSLLY CSL Limited
- RVMD Revolution Medicines, Inc.
- CMXHF CSL Limited
- ALNY Alnylam Pharmaceuticals, Inc.
- RPRX Royalty Pharma plc
- INCY Incyte Corporation
- INSM Insmed Incorporated
- GNMSF Genmab A/S
Every healthcare company we cover is on the Healthcare hub.
Common questions
Which funds own HUMA?
7 of the institutions we track reported a position in HUMA in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
When does HUMA report earnings next?
Humacyte, Inc. is scheduled to report on 12 Nov 2026. Companies move earnings dates, so read it as scheduled rather than certain.
Where does SteadyShares get its HUMA data?
Fundamentals for HUMA come from company filings and exchange data, as listed on NMS; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 05:51 UTC and is delayed. Our data quality score for this company is 83/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for HUMA, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.